Eisai weight-loss drug reduces diabetes risk

Eisai (TYO: 4523) has presented data showing the potential of its anti-obesity drug Belviq (lorcaserin hydrochloride) to prevent and cause remission of type 2 diabetes.

The Japanese pharma major presented the results from a long-term cardiovascular outcomes trial at the annual meeting of the European Association for the Study of Diabetes (EASD), in Berlin, and they were concurrently published in The Lancet.

This new analysis assessed metabolic effects on enrolled patients with type 2 diabetes or pre-diabetes at baseline, as well as patients with normoglycemia.